Results 31 to 40 of about 16,301 (208)

Genomic organization, expression analysis, and chromosomal localization of the mouse PEX3 gene encoding a peroxisomal assembly protein [PDF]

, 2000
The peroxin Pex3p has been identified as an integral peroxisomal membrane protein in yeast where pex3 mutants lack peroxisomal remnant structures.
Muntau, Anja C., Muntau, AC, Mayerhofer, Peter U., Albet, Sabrina, Bugaut, Maurice, Bugaut, M, Mayerhofer, PU, Roscher, AA, Albet, S, Kammerer, S, Schmid, Thomas E., Roscher, Adelbert A., Kammerer, Stefan, Schmid, TE   +13 more
core   +1 more source

The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study

BMC Ophthalmology, 2018
Background Previous studies suggested that use of fenofibrate could significantly reduce the rate of progression into diabetic retinopathy (DR), and that retinal nerve fiber layer (RNFL) loss, which has been considered an important indicator for retinal ...
Rui Shi, Lei Zhao, Yun Qi
doaj   +1 more source

A Novel Class of “Super‐Strained” Spiro Heterocycles: Gateway to 1‐Azaspiro[3.3]heptane Derivatives, and Biological Validation

Angewandte Chemie, EarlyView.
A new class of “super‐strained” spiro heterocycles—spirocyclic 1‐azabicyclo[1.1.0]butanes—was synthesized via insertion of cyclobutane‐, oxetane‐, and azetidine‐containing sulfonium reagents into substituted azirines. The stability of this new class of compounds was studied.
Philipp Natho, Annarita Vicenti, Marco Colella, Francesco Pasca, Giuseppe Romanazzi, Mauro Niso, Carmen Abate, Ernesto Mesto, Emanuela Schingaro, Renzo Luisi   +9 more
wiley   +2 more sources

Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome

Journal of Lipid Research, 2012
We examined the effects of fenofibrate and atorvastatin on very low density lipoprotein (VLDL) apolipoprotein (apo)E metabolism in the metabolic syndrome (MetS). We studied 11 MetS men in a randomized, double-blind, crossover trial.
Esther M.M. Ooi, Theodore W.K. Ng, Gerald F. Watts, Dick C. Chan, P. Hugh R. Barrett   +4 more
doaj   +1 more source

Fenofibrate and Crataegus oxyacantha is an effectual combo for mixed dyslipidemia

Biomedical and Biotechnology Research Journal, 2020
Background: Dyslipidemia (DL) is a blood lipid disorder characterized by high cholesterol, triglyceride and low density lipoprotein with reduction of high density lipoprotein.
Huda A Rasheed, Nawar R Hussien, Marwa S Al-Naimi, Hayder M Al-Kuraishy, Ali I Al-Gareeb   +4 more
doaj   +1 more source

Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization

Biology, 2021
Macular edema caused by retinal vascular leakage and ocular neovascularization are the leading causes of severe vision loss in diabetic retinopathy (DR) and age-related macular degeneration (AMD) patients.
Li Huang, Wentao Liang, Kelu Zhou, Ronald A. Wassel, Zachary D. Ridge, Jian-Xing Ma, Bing Wang   +6 more
doaj   +1 more source

Fenofibrate Decreases Hepatic P-Glycoprotein in a Rat Model of Hereditary Hypertriglyceridemia

Frontiers in Pharmacology, 2019
P-glycoprotein (P-gp) is a membrane-bound transporter encoded by Mdr1a/Abcb1a and Mdr1b/Abcb1b genes in rodents involved in the efflux of cytotoxic chemicals and metabolites from cells.
Martin Poruba, Zuzana Matuskova, Zuzana Matuskova, Martina Hüttl, Hana Malinska, Olena Oliyarnyk, Irena Markova, Sona Gurska, Ludmila Kazdova, Rostislav Vecera   +9 more
doaj   +1 more source

Genetic Risk Scores Associated with Baseline Lipoprotein Subfraction Concentrations Do Not Associate with Their Responses to Fenofibrate

Biology, 2014
Lipoprotein subclass concentrations are modifiable markers of cardiovascular disease risk. Fenofibrate is known to show beneficial effects on lipoprotein subclasses, but little is known about the role of genetics in mediating the responses of lipoprotein
Alexis C. Frazier-Wood, Mary K. Wojczynski, Ingrid B. Borecki, Paul N. Hopkins, Chao-Qiang Lai, Jose M. Ordovas, Robert J. Straka, Micheal Y. Tsai, Hemant K. Tiwari, Donna K. Arnett   +9 more
doaj   +1 more source

Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats

Journal of Lipid Research, 2002
The level of maternal circulating triglycerides during late pregnancy has been correlated to newborns' weight in humans. To investigate the response to fenofibrate, a hypotriglyceridemic agent, in pregnant rats, 0, 100, or 200 mg of fenofibrate/kg body ...
Ana Soria, Carlos Bocos, Emilio Herrera
doaj   +1 more source

Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review [PDF]

Diabetes & Metabolism Journal
Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk.
Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang   +2 more
doaj   +1 more source